Evidence map›Paper›PMID 25891142›Full record

ReviewAnnals of the New York Academy of Sciences2015

Antimalarial drug resistance in Africa: key lessons for the future.

Shannon Takala-Harrison, Miriam K Laufer

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of the New York Academy of Sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. The Global Landscape ofPathogens (Basel, Switzerland) · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Optimization of diastereomeric dihydropyridines as antimalarials.European journal of medicinal chemistry · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shannon Takala-HarrisonCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland.
Miriam K Laufer

Funding

Genome-wide studies to identify markers of artemisinin-resistant malariaR01AI101713 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI HARRISON, SHANNON TAKALA · 2013 to 2016
$1.8M
NIAID NIH HHS R01 AI101713
6 · The paper itself

Abstract

Drug-resistant parasites repeatedly arise as a result of widespread use of antimalarial drugs and have contributed significantly to the failure to control and eradicate malaria throughout the world. In this review, we describe the spread of resistance to chloroquine and sulfadoxine-pyrimethamine, two old drugs that are no longer used owing to high rates of resistance, and examine the effect of the removal of drug pressure on the survival of resistant parasites. Artemisinin-resistant malaria is now emerging in Southeast Asia in a unique and unexpected pattern. We will review the most recent genomic and clinical data to help predict the behavior of resistance to new antimalarial medications and inform strategies to prevent the spread of drug-resistant malaria in Africa in the future.

Indexed as

AfricaAnimalsAntimalarialsArtemisininsChloroquineDrug CombinationsDrug ResistanceDrug Therapy, CombinationForecastingHumansMalariaPyrimethamineSulfadoxineAntimalarialsartemisininArtemisininsChloroquineDrug Combinationsfanasil, pyrimethamine drug combinationPyrimethamineSulfadoxineAfricaartemisinin-based combination therapyartemisinin resistancedrug resistancemalariamolecular epidemiology

Identifiers

PMID25891142
PMCPMC4527866

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.